News

GSK enters US$200m PPP
Enlarge image

BusinessUK

GSK enters US$200m PPP

24.05.2013 - GSK has entered into a public-private partnership with the federal US agency BARDA to develop new antibiotics and drugs against potential bioweapons.

The first-ever public-private partnership of the Biomedical Advanced Research and Development Authority (BARDA) with a pharma company could be worth up to US$200m if the collaboration proves effective after 18 months. The two partners will jointly develop anti-infectives to treat infections with bugs that have become a medical threat due to their resistance to common antibiotics. Additionally, the collaboration aims at developing drugs against pathogens that could become a civil threat due to their potential use as a bioweapon. Both topics are priorities of the National Health Security Strategy as well as the BARDA’s 2011-2016 working plan.

The initial funding for the Public-Private Partnership of US$40m for the first 18 months will give GSK the possibility to further develop promising candidates from its antibiotics portfolio with a lowered investment risk for the drugmaker. While return-on-investment in the antibiotics space has become low, most large drug-makers have focused on more lucrative and financially less risky disease areas. David Payne, head of GSK's antibacterial discovery unit, said public-private partnerships, like the one with BARDA, were a key part to solving the problem.

GSK is already involved in the Innovative Medicine’s Initiative’s programme against antibiotic resistance. But while the IMI programme is focused on bringing Phase III drugs to the market and to find strategies against Gram-negative bacteria, the compounds covered by the BARDA deal are still in early safety testing.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/gsk-enters-us200m-ppp.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • FORMYCON24.58 EUR6.18%
  • CYTOS1.45 CHF3.57%

FLOP

  • MEDIGENE10.52 EUR-9.70%
  • BIOFRONTERA2.53 EUR-3.44%
  • 4SC1.25 EUR-2.34%

TOP

  • CYTOS1.45 CHF326.5%
  • MEDIGENE10.52 EUR147.5%
  • 4SC1.25 EUR60.3%

FLOP

  • MORPHOSYS56.55 EUR-24.4%
  • WILEX3.00 EUR-12.5%
  • BASILEA108.00 CHF-11.6%

TOP

  • SANTHERA92.40 CHF2269.2%
  • WILEX3.00 EUR400.0%
  • FORMYCON24.58 EUR251.1%

FLOP

  • CYTOS1.45 CHF-51.3%
  • MOLOGEN5.81 EUR-48.7%
  • PAION2.34 EUR-29.9%

No liability assumed, Date: 29.03.2015